Bristol Myers wins a megablockbuster bet with TYK2 FDA approval — and there's a big bonus for the label

John Carroll

Editor & Founder

Amber Tong

Bristol Myers Squibb made a megablockbuster bet on deucravacitinib, an in-house experimental TYK2 drug, in the leadup to the big Celgene buyout, keeping it while …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Bristol Myers wins a megablockbuster bet with TYK2 FDA approval — and there's a big bonus for the label

John Carroll

Editor & Founder

Amber Tong

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

After stock slides, Amgen addresses bone density talk on obesity drug

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Bris­tol My­ers wins a megablock­buster bet with TYK2 FDA ap­proval — and there's a big bonus for the la­bel

Editor & Founder

Sign up to read this article for free.

Bristol Myers wins a megablockbuster bet with TYK2 FDA approval — and there's a big bonus for the label